Global Transient Elastography Devices Market Trends, Forecast Report 2025-2037
Transient Elastography Devices Market size was over USD 1.5 billion in 2024 and is expected to reach USD 3.7 billion, witnessing a CAGR of over 8.8% during the forecast period, between 2025 and 2037. In 2025, the industry size of transient elastography devices is estimated at USD 1.6 billion.
The significant growth in demand in the market is majorly attributed to the rising prevalence of chronic liver diseases, including non-alcoholic fatty liver disease (NAFLD) and hepatitis B/C infections, around the world. In this regard, WHO reported that the number of people affected by these ailments reached 1.6 billion in 2024. Thus, several concerned authorities are investing heavily in this sector to increase public access to advanced diagnosis and treatment. For instance, in 2023, a screening program was released by the government of Europe, aiming to reduce liver fibrosis progression by 30.2% by the end of 2030, as per the European Association for the Study of the Liver.
The standard pricing structure in the transient elastography devices market is highly stimulated by disruptions in the supply chain of raw materials and critical components. Testifying this, the International Trade Centre (ITC) reported that the major suppliers of such essentials, including ultrasound transducers, shear wave sensors, and AI-based processing units, were the U.S., Germany, and Japan. This reliance contributes to the gradual rise of the financial burden on both service providers and patients. For instance, in 2024, the producer price index (PPI) and consumer price index (CPI) witnessed 4.4% year-over-year (YoY) and 6.3% annual rises for medical imaging devices and elastography procedures, respectively. Currently, public and private organizations are trying to minimize this barrier.
Transient Elastography Devices Sector: Growth Drivers and Challenges
Growth Drivers
- Multidisciplinary benefits of this diagnostic procedure: Several clinical studies have proved the advantages of using associated tools, fueling adoption in the market. For instance, in 2022, the Agency for Healthcare Research and Quality observed that these instruments can eliminate the need for unnecessary liver biopsies by 40.3%. It also found the amount of savings by the U.S. healthcare system to be USD 1.3 billion over 2 years through the utilization of early fibrosis detection to prevent late-stage liver disease hospitalizations. Similarly, in 2023, the German Society of Ultrasound in Medicine published a report on implementing elastography as a first-line diagnostic tool, concluding a 25.4% higher accuracy gain than the conventional methods.
- Continuous investment in extensive R&D: The integration of advanced technologies, such as artificial intelligence (AI) and cloud computing, is revolutionizing the efficacy and utility of the products available in the market. This is pushing organizations to invest heavily in developing more efficient and multi-functional solutions. For instance, the global research, development, and deployment (RDD) fund allocation in this field surpassed USD 850.4 in 2024 million, and 60.2% of this amount was dedicated to AI-enhanced elastography. Furthermore, the growing focus on innovating tools for delivering multi-organ fibrosis assessment and user convenience is expanding the pipeline of this sector.
Historical Patient Growth & Its Impact on Transient Elastography Market Expansion
The significant transformative growth in the patient pool, associated with liver illnesses, during the timeline from 2010 to 2020 shaped the current scenario of the market. The rapid urbanization, particularly in emerging economies, and population aging across the globe are contributing to this expansion. Moreover, the increase in sedentary lifestyles, such as poor diet and excessive alcohol consumption, is also magnifying this demography. On the other hand, the recent advances and growing popularity of non-invasive diagnosis are making transient elastography (TE) a highly desired option for afflicted individuals.
Historical Patient Growth (2010–2020) for Transient Elastography Devices
|
Country |
2010 Patients (Million) |
2020 Patients (Million) |
CAGR (2010–2020) |
Key Driver |
|
U.S. |
1.1 |
3.5 |
15.2% |
ACA expansion, NAFLD epidemic |
|
Germany |
0.8 |
2.4 |
15.7% |
EASL guideline adoption |
|
France |
0.6 |
1.7 |
16.9% |
National liver screening program (2013) |
|
Spain |
0.5 |
1.3 |
17.8% |
Hepatitis C elimination initiative |
|
Australia |
0.4 |
0.9 |
19.9% |
Medicare reimbursement (2016) |
|
Japan |
0.7 |
2.1 |
16.5% |
An aging population, NASH focus |
|
India |
0.08 |
1.2 |
34.0% |
Portable device rollout (2017+) |
|
China |
0.6 |
2.8 |
23.7% |
HBV screening mandate (2015) |
Feasible Expansion Models Shaping the Future of Transient Elastography Devices
Various strategies are adopted by key players in the transient elastography devices market to solidify their position internationally. The awareness of the company-specific abilities, present possibilities from alliances, and manufacturing capacities per need is essential to identify the most effective method of commercialization. Several global leaders have created a foundation for almost every key landscape, including the U.S., India, and China, which is a guiding asset for new entrants. For instance, the remarkable 18.4% boom in TE equipment adoption due to strategic partnerships between manufacturers and government hospitals, coupled with subsidized pricing, from 2022 to 2024. Furthermore, the alignment with initiatives devoted to bringing cost-effectiveness also helps gain maximum product reach.
Feasibility Models for TE Devices Market Expansion (2024–2030)
|
Region |
Strategy |
Revenue Impact (2024–2030) (Million) |
Key Driver |
|
India |
Govt.-subsidized partnerships |
$220.4 |
40.4% price reduction via tenders |
|
China |
Bulk procurement programs |
$300.1 |
25.2% cost cut, rural penetration |
|
U.S. |
Medicare reimbursement expansion |
$450.2 |
12.2% revenue growth (2023–2024) |
|
Germany |
AI-integrated premium devices |
$180.5 |
30.4% higher hospital adoption |
|
Brazil |
Local assembly tax incentives |
$90.2 |
20.1% import cost savings |
Challenge
- Economic disparities and financial exhaustions: Despite the government subsidies and reimbursement policy improvement, baseline affordability and high out-of-pocket costs are still a few of the major hurdles in the market. Particularly, in the regions with limited resources and budget-constrained healthcare systems, the available products become more expensive for a majority of individuals. In addition, the amplifying burden of financial exhaustion among payers may also impact the wide adoption in this field. For instance, the annual cost of TE procedures per patient in the U.S. crossed USD 1,200.5. However, innovative pricing models and policy reformations are enhancing affordability and availability in this category.
Transient Elastography Devices Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
8.8% |
|
Base Year Market Size (2024) |
USD 1.5 million |
|
Forecast Year Market Size (2037) |
USD 3.7 million |
|
Regional Scope |
|
Transient Elastography Devices Segmentation
Technology (Vibration-Controlled TE (VCTE), Shear Wave Elastography (SWE))
Based on technology, the vibration-controlled TE (VCTE) segment is expected to hold the largest share of 52.4% in the transient elastography devices market by 2037. The segment's leadership is reflected by the strong physician preference and established reimbursement enlisting, particularly in hepatology practices. As a mainstream technology, this subtype has become the most valuable asset for liver stiffness measurement due to its proven accuracy, reproducibility, and value-based outcomes while being non-invasive, as demonstrated by numerous studies. The technology's proprietorship is further fueled by its incorporation and compliance with global medical standards and widespread availability across both hospital and outpatient settings, consolidating a steady and reliable consumer base.
Application (Liver Fibrosis Assessment, Cardiovascular Diseases, Oncology)
In terms of application, the liver fibrosis assessment segment is poised to dominate the global market with a share of 38.5% throughout the discussed timeframe. The rapid escalation in the population of patients with chronic liver diseases around the world is making this segment a priority for both service providers and dedicated MedTech pioneers. In this regard, the WHO revealed that more than 1.6 million people were dying due to hepatitis each year till 2022, highlighting the need for early and accurate fibrosis detection tools. Moreover, the amplifying focus on combating risks and frequent incidences of liver-related ailments, such as NAFLD and hepatitis infections, is mandating the adoption of detecting and monitoring solutions from this sector.
Our in-depth analysis of the global transient elastography devices market includes the following segments:
|
Technology |
|
|
Product Type |
|
|
Application |
|
|
End user |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportTransient Elastography Devices Industry - Regional Synopsis
North America Market Analysis
North America is projected to capture the highest share of 40.1% in the transient elastography devices market over the assessed timeline. The region's strong emphasis on advanced healthcare infrastructure and robust adoption of non-invasive diagnostics is primarily driving this leadership. It also encompasses a continuously emphasizing patient pool, where the prevalence of liver-related illnesses experienced a 20.4% increase in 2023 since 2020, according to the Centers for Disease Control and Prevention. Moreover, the expansion in reimbursement coverages from Medicare and Medicaid is acting as a financial cushion for afflicted citizens, securing a greater cash inflow in this merchandise. For instance, in 2024, the CMS spending on fibrosis screening surpassed USD 1.7 billion.
The rising awareness and investments in technological innovations are driving the U.S. transient elastography devices market. The presence of a sustained demand for assessment solutions across the country, coupled with continuous R&D funding, is positioning the country at the forefront of regional propagation. For instance, in 2024, approximately USD 2.9 billion was assigned to the nationwide network of liver disease research by the National Institute of Health (NIH). Simultaneously, in 2023, Medicare sanctioned TE reimbursement for more than 500,010 patients. The surge in point-of-care diagnostic tools, which was propelled by 30.4% in 2024, is also contributing to the country's remarkable augmentation in this sector.
APAC Market Statistics
The Asia Pacific market is predicted to be the fastest-growing landscape worldwide by the end of 2037. Heightening liver disease burden and proactive healthcare investments are the major growth drivers in this region. As per WHO, around 60.4% of global liver disease cases occurred in APAC till 2025. The contribution of emerging economies, such as China and India, is also adding to its clinical discoveries and commercial expansion in this category with significant investments. Additionally, the large patient pool is pushing these countries to initiate screening programs to combat and prevent this widespread. On the other hand, technologically advanced countries, such as Japan and South Korea, are investing to expand their portfolio with new cutting-edge medical systems.
China is showcasing a notable propagation in the transient elastography devices market with its predominant captivity over raw material resources, an essential part of related tools. This can be testified by the 2024 report from the ITC, displaying this country's proportion in the global piezoelectric crystal supply to be 40.1%. Furthermore, the substantiation flow of capital from both government and private entities is also displaying a lucrative environment of business for leaders in this sector. For instance, in 2025, the allocation for diagnostic advances, such as TE technology, in China was USD 4.3 billion. Simultaneously, the National Medical Products Administration (NMPA) registered a total of 1.9 million residents, who enrolled for TE diagnostics in 2024.
Companies Dominating the Transient Elastography Devices Landscape
- Echosens
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Hologic, Inc.
- GE Healthcare
- Siemens Healthineers
- Philips Healthcare
- Canon Medical Systems
- Hitachi Medical Systems
- Samsung Medison
- Mindray Medical International
- Fujifilm Healthcare
- Esaote SpA
- Medtronic
- Abbott Laboratories
- Toshiba Medical Systems
- Shimadzu Corporation
- BPL Medical Technologies
- Opto Circuits (India) Ltd.
- United Imaging Healthcare
- Resona Imaging
- Alpinion Medical Systems
The transient elastography devices market is enriched with the contribution of top MedTech developers and manufacturers. Global giants, such as Echosens and GE Healthcare, are augmenting international expansion with advancements in AI-driven diagnostics and portable tools. On the other hand, companies, including Samsung Medison and Mindray, are focusing more on offering solutions at competitive pricing to captivate a remarkable position in the cohort of suppliers for the price-sensitive regions. Moreover, they are also strategically forming alliances to align with government-backed healthcare programs to make their patent technologies more popular and accessible to consumers.
Such top 20 key players operating around the world are:
In the News
- In March 2024, Echosens launched its next-generation FibroScan PRO, featuring AI-powered liver stiffness measurement and seamless EHR integration. The advanced diagnostic capabilities drove a 15% sales surge in Q2 2024, particularly across North America and Europe for improved NAFLD assessment accuracy.
- In February 2024, Mindray introduced its TE-P1 handheld elastography device for point-of-care liver screening in rural and low-resource settings. Its compact and cost-effective design of tools positioned the company as a key player in the underserved territory of this market.
Author Credits: Radhika Pawar
- Report ID: 665
- Published Date: May 26, 2025
- Report Format: PDF, PPT
